Scorpius Holdings, Inc.

SCPX

US42237K4094

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:10:00 2024-05-01 pm EDT			5-day change	1st Jan Change
0.1838 ^USD	-4.27%		+14.30%	-58.26%

Apr. 26	Scorpius Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 23	Scorpius Holdings Gets Non-Compliance Notice From NYSE American	MT

NightHawk Biosciences, Inc. has Changed its Ticker to SCPX from NHWK

January 08, 2024 at 12:00 am EST

Effective January 08, 2024, NightHawk Biosciences, Inc. changed its NYSE MKT LLC stock ticker symbol to SCPX from NHWK.

Latest news about Scorpius Holdings, Inc.

Scorpius Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Scorpius Holdings Gets Non-Compliance Notice From NYSE American	Apr. 23	MT
North American Morning Briefing : Stock Futures -2-	Apr. 11	DJ
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
US Stock Futures Flat Ahead of Powell Speech After Reaching Record Highs on Thursday	Mar. 22	MT
Scorpius Holdings, Inc. Wins Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University	Mar. 19	CI
Scorpius Closes $1.5 Million Public Offering	Mar. 13	MT
Scorpius Holdings Prices Stock Offering at $0.15 a Share	Mar. 08	MT
Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023	Mar. 07	CI
NightHawk Biosciences, Inc. will Change its Name to Scorpius Holdings, Inc	Feb. 06	CI
Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary	Feb. 01	CI
NightHawk?s Scorpius BioManufacturing Subsidiary Receives Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program	Jan. 25	CI
NightHawk Biosciences Postpones Planned Name Change	Jan. 22	MT
Nighthawk?S Scorpius Biomanufacturing Subsidiary Commences Work on Preclinical Program for New Client	Jan. 16	CI
NightHawk Biosciences, Inc. Announces Executive Appointments	Jan. 08	CI
NightHawk Biosciences, Inc. has Changed its Ticker to SCPX from NHWK	Jan. 08	CI
Scorpius BioManufacturing Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement for A Leading National University	Jan. 03	CI
Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc..	Dec. 26	CI
NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding	Dec. 10	CI
NightHawk Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Jeffrey Wolf submitted a preliminary, non-binding offer letter to acquire Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. for $40.5 million.	23-08-20	CI
NightHawk Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
NightHawk Biosciences, Inc.(NYSEAM:NHWK) dropped from Russell Microcap Value Index	23-06-23	CI
NightHawk Biosciences, Inc.(NYSEAM:NHWK) dropped from Russell 3000E Value Index	23-06-23	CI
NightHawk Biosciences, Inc.(NYSEAM:NHWK) dropped from Russell 3000E Index	23-06-23	CI

Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Scorpius Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.1838 USD

Average target price

10 USD

Spread / Average Target

+5,340.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SCORPIUS HOLDINGS, INC.	-58.26%	6.92M
KYOWA KIRIN CO. LTD.	+12.26%	9B
SK BIOPHARMACEUTICALS CO., LTD.	-12.75%	4.96B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+42.38%	4.47B
YUHAN CORPORATION	+5.23%	3.9B
INDIVIOR PLC	+20.51%	2.45B
BETTA PHARMACEUTICALS CO., LTD.	-19.05%	2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.72%	2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.13%	2.02B
SUPERNUS PHARMACEUTICALS, INC.	+3.94%	1.65B

Specialty & Advanced Pharmaceuticals

Scorpius Holdings, Inc.

Equities

SCPX

US42237K4094

Pharmaceuticals

NightHawk Biosciences, Inc. has Changed its Ticker to SCPX from NHWK

Latest news about Scorpius Holdings, Inc.

Chart Scorpius Holdings, Inc.

Company Profile

Income Statement Evolution

Ratings for Scorpius Holdings, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals